DHR — Q3 2026 Financial Report Analysis

Danaher's third-quarter sales rose 8.3% to $6.55 billion (the company rounds this to 8.5%). Almost all of that came from Masimo, the patient-monitoring maker it bought for $9.8 billion in June. Core sales grew 3.0%; "core" is Danaher's measure that strips out acquisitions, currency moves and, from this quarter, tariff refunds passed back to customers. Excluding respiratory (flu and COVID) testing, core growth was 5.5%. GAAP earnings per share jumped 34.5% to $1.71, but $0.37 of that is a one-off tax benefit. Adjusted EPS, the company's figure that excludes acquisition amortization and other items, rose 11.5% to $2.11. Management raised its full-year adjusted EPS range to $8.57–$8.62, but it also lowered its full-year core growth forecast.

Headline numbers

Operating margin is the share of sales left after running the business, before interest and tax. Free cash flow is operating cash flow minus spending on equipment and buildings.

Where the growth came from

Danaher's own bridge from reported to core growth: acquisitions added 6.5 points, currency had no material effect, and tariff refunds returned to customers took 1.0 point off reported sales. That leaves 3.0% core growth. Respiratory testing cost a further 2.5 points, which is why core growth excluding it was 5.5%. Average prices fell 0.5%, so the growth came from selling more units, not from charging more.

• Biotechnology sells equipment and consumables for making biologic drugs. Reported sales were nearly flat, but core sales grew 5.0%; the gap is mainly tariff refunds handed back to customers, which cut reported sales by 4.0 points. Bioprocessing core sales grew "towards the upper end of mid-single digits," mostly from consumables, the filters and media that customers buy again with every production run. Equipment sales also improved. The smaller discovery and medical business shrank. The 680-basis-point margin gain (100 basis points = 1 percentage point) breaks down as 490 points from higher volume, IEEPA tariff refunds and cost leverage, and 190 points because Q3 2025 carried intangible-asset impairments, net of a 2026 facility impairment.
• Life Sciences grew core sales 4.5%. Filtration led, on demand for microelectronics and aerospace products, followed by flow cytometry, lab automation and mass spectrometry. The 10-Q says mass spectrometry saw "a modest improvement in academic spending in the United States." Of the 150-point margin gain, 45 points came from a one-off settlement of an acquisition-related contingency.
• Diagnostics reported 17.0% sales growth, of which 16.5 points was acquisitions (about $400 million, almost all Masimo). Core growth was only 0.5% because respiratory test demand fell. Excluding respiratory, core growth was 7.0%, led by the clinical lab business. Core sales in China grew year over year even though China's volume-based procurement program (centralized tenders that force price cuts) still cut segment prices by 1.0%. The margin fell 570 basis points: 365 from Masimo's lower margin and 295 from an inventory accounting charge, explained below.

By region, core sales in high-growth markets rose 10%, with China up high single digits. Developed markets were flat: Western Europe grew mid-single digits, but North America fell low-single digits because of weaker respiratory sales.

What the headline numbers hide

• The GAAP EPS jump is mostly tax. Q3 had a tax benefit of $75 million, where a year earlier it had a $168 million tax expense. That came from $263 million of discrete tax benefits, mainly reserves released after audits were settled. The release attributes $0.37 per share to "discrete tax adjustments." A separate $28 million release (about $0.04) shows up in discontinued operations, linked to old tax returns filed jointly with Veralto and Fortive. Management still expects a full-year tax rate of about 17%, so this will not recur.
• What adjusted EPS excludes. The $0.40 gap between GAAP EPS ($1.71) and adjusted EPS ($2.11) is made up of acquisition amortization (+$0.73; $513 million pre-tax, up from $433 million because of Masimo), the Masimo inventory step-up (+$0.12; $84 million pre-tax), a facility impairment (+$0.07), investment losses (+$0.02) and special equity awards (+$0.02). Against those: the tax effect of the adjustments (−$0.17), the discrete tax release (−$0.37) and the contingency settlement (−$0.01).
• Margin was depressed by one inventory charge. Accounting rules require acquired inventory to be revalued up to fair value, so Masimo's first products sold carry a higher cost. That added $84 million to cost of sales this quarter and took 130 basis points off group operating margin. It ends once the acquired inventory has been sold. Without it, the margin would have been about 20.3% rather than 19.0%.
• Tariff refunds help adjusted EPS too. Refunds of IEEPA tariffs that Danaher paid earlier, after the February 2026 Supreme Court ruling, are booked as lower cost of sales. Adjusted EPS does not exclude them. The 10-Q puts their net-earnings benefit, after refunds passed to customers, at "less than $100 million." In every segment's margin discussion they are bundled with volume gains, so the filing does not show how much of the margin improvement is a refund that will not recur.
• Where the EPS growth came from. Adjusted EPS rose 11.5% while operating profit rose 7.9%. Diluted shares fell about 1% (706.8 million vs 713.7 million), which helped. Net interest expense went the other way: it rose to $104 million from $64 million because of Masimo-related borrowing.
• Cash conversion is healthy. Operating cash flow was 1.56x continuing net earnings in the quarter (1.83x a year ago, when earnings were smaller) and free cash flow grew 19%. Inventory has risen to $3.13 billion from $2.49 billion in December, but most of that came with Masimo. The cash flow statement shows only $229 million of inventory build from operations year to date, in line with $242 million last year. Receivables rose just 5% from December.
• The balance sheet has changed. Total debt is $26.5 billion, up from $18.4 billion at year-end. Cash is $5.7 billion, so net debt is about $20.8 billion versus about $13.8 billion. Danaher bought back no stock in Q3, against $2.0 billion a year ago.

Did last time's read hold up?

Our Q2 2026 report said the second half depended on three things.

1. Bioprocessing orders turning into shipments: mostly yes. Bioprocessing core sales grew toward the upper end of mid-single digits, including better equipment sales.
2. Respiratory testing no longer a drag by Q4: no. The new Q4 outlook still has respiratory testing about 1.5 points behind.
3. Masimo integrated without further margin dilution: not yet. Diagnostics margin fell 5.7 points.

Q3 itself beat the guidance we reported. Core growth was 3.0%, at the top of the 2.0%–3.0% range. Core growth excluding respiratory was 5.5%, against about 5%. Net interest expense was $104 million, against about $115 million guided.

Takeaway: The underlying business is speeding up. Core growth excluding respiratory testing was 5.5%, up from 4.5% in Q2, and bioprocessing consumables are leading again. But the raised EPS guidance rests partly on a tax release and tariff refunds. Meanwhile the full-year core growth forecast fell to about 2.5% from 3–4%, and respiratory testing will still be a drag in Q4. The result is a better earnings year than July's forecast, but with less sales growth.

Outlook

From the October 21 earnings release (Form 8-K Exhibit 99.1):

• Q4 2026: core growth excluding respiratory of 4.0%–5.0%, a respiratory drag of about 1.5 points, and total core growth of about 3.0%. By segment, Biotechnology is guided to mid-single digits, Life Sciences to 4%–5% and Diagnostics to "up slightly."
• Full year 2026: adjusted EPS of $8.57–$8.62, up from $8.45–$8.60. Total core growth of about 2.5%, mid-single digits excluding respiratory. Tax rate about 17%, about $1.9 billion of acquisition amortization, and about $305 million of net interest expense.
• The guidance implies Q4 adjusted EPS of about $2.46–$2.51 (the full-year range minus the $6.11 earned through nine months).
• The release also flags about $200 million of stock-based compensation for special equity awards. That includes a $185 million charge for awards that have been canceled, which will weigh on Q4 GAAP results.

Our read: the direction is right, but the forecast now rests on a smaller sales base. Underlying demand is improving: China, pharma and biotech customers are buying more, and even US academic spending ticked up in mass spectrometry. The Q4 guide of 4–5% excluding respiratory is roughly where Q3 already landed, so it does not require further acceleration. Q3 itself beat guidance. The cut to full-year core growth comes from a lower Q4 forecast: about 3% total core growth, against the mid-single-digit Q4 growth guided in July, mainly because respiratory testing is still expected to be a drag. Three things to watch in Q4. First, whether Diagnostics margins start to recover once the Masimo inventory charge has passed. Second, how much of the margin gain was tariff refunds, which would not come back in 2027. Third, whether Danaher uses its roughly $1.6 billion of quarterly free cash flow to pay down Masimo debt before restarting buybacks.

Source: Danaher Form 10-Q for the quarter ended September 25, 2026. Adjusted EPS, free cash flow and guidance are from the Q3 2026 earnings release (Form 8-K Exhibit 99.1, October 21, 2026).